About Madrigal Pharmaceuticals
Founded in 2016, we are a biopharmaceutical company developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). MASH is a serious fatty liver disease that can cause progressive liver scarring (fibrosis), cirrhosis, liver failure, liver cancer, transplant needs, and early death. We aim to halt or reverse liver scarring and resolve MASH before patients experience these severe complications.
Our research program identified a thyroid hormone receptor-β (THR-β) agonist as our lead therapeutic candidate. In 2024, we received the first U.S. Food and Drug Administration (FDA) approval for a MASH treatment and subsequently launched it in the U.S.
What started as a small team in Conshohocken, Pennsylvania, has grown into a fully integrated biopharmaceutical company operating in the United States and Europe. Our corporate headquarters are in West Conshohocken, PA, with additional offices in Waltham, MA, and Zug, Switzerland.
Mission & Values
Our purpose is to lead the fight against MASH. We aim to protect patients and the health system by halting and reversing MASH before severe complications like cirrhosis, liver cancer, liver transplant, or early death occur.
Our culture is built on our Core Values:
- Patient Focus: We prioritize patients to guide our work, developing new treatments for MASH and addressing unmet needs.
- Owner Mindset: We take individual accountability and ownership to achieve results and deliver on our promises.
- Relentless Pursuit of Innovation: We think creatively, solve problems, and embrace new ideas to drive innovation.
- Commitment to Collaboration: We foster an inclusive and collaborative culture, recognizing that every success comes from teamwork and a shared passion to improve lives.
Team & Culture
We are a fully integrated biopharmaceutical company with 501-1000 employees across the United States and Europe. Every team member shares the purpose of leading the fight against MASH.
We foster a collaborative, respectful, and entrepreneurial culture. We bring together individuals with diverse backgrounds and expertise, all dedicated to making a meaningful difference in the lives of people living with MASH. We are an Equal Opportunity Employer, basing employment decisions on qualifications, merit, and business need.
Frequently Asked Questions
Madrigal Pharmaceuticals develops and delivers novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). In 2024, the company achieved the first U.S. FDA approval for a treatment in MASH and subsequently launched this treatment in the U.S.
Madrigal Pharmaceuticals fosters a collaborative, respectful, and entrepreneurial culture. The company emphasizes a patient focus, an owner mindset, a relentless pursuit of innovation, and a commitment to collaboration. It values diverse backgrounds, perspectives, and expertise among its team members, who are dedicated to making a meaningful difference for people living with MASH.
Madrigal Pharmaceuticals’ purpose is to lead the fight against MASH. This involves protecting patients and the health system by halting and reversing MASH before it leads to devastating liver complications, such as cirrhosis, hepatocellular carcinoma, liver transplant, or mortality.
Madrigal Pharmaceuticals was founded in 2016.
Madrigal Pharmaceuticals is active in the Liver Disease, Nash, Metabolic Disease, and Mash markets.
Madrigal Pharmaceuticals has 501-1000 employees.
Madrigal Pharmaceuticals hires globally with a remote-first approach, allowing employees to work from anywhere.
Madrigal Pharmaceuticals is not actively hiring at the moment. Check back later for new opportunities.
Yes, Madrigal Pharmaceuticals is a remote-first company.
Madrigal Pharmaceuticals's website is www.madrigalpharma.com .
You can find Madrigal Pharmaceuticals on X (Twitter) and LinkedIn .
Remote companies like Madrigal Pharmaceuticals
Find your next opportunity with companies that specialize in Liver Disease, Nash, Metabolic Disease, and Mash. Explore remote-first companies like Madrigal Pharmaceuticals that prioritize flexible work and home-office freedom.

Axsome Therapeutics, Inc.
Develops novel therapies for central nervous system conditions with limited treatment options.

Terns Pharmaceuticals
Developing small-molecule therapies

Biofourmis
Provides AI-driven solutions for remote patient monitoring and care delivery, enabling hospital-level services at home.

VirtualHealth
Provides the HELIOS® care management platform and advisory services for healthcare organizations.
Project: Career Search
Rev. 2026.2
[ Remote Jobs ]
Direct Access
We source jobs directly from 21,000+ company career pages. No intermediaries.
Discover Hidden Jobs
Unique jobs you won't find on other job boards.
Advanced Filters
Filter by category, benefits, seniority, and more.
Priority Job Alerts
Get timely alerts for new job openings every day.
Manage Your Job Hunt
Save jobs you like and keep a simple list of your applications.


